Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ selected allogeneic hematopoietic stem cells (Sidney Kimmel Cancer Center)
- Development stage
- Preclinical
- Lead developer
- Sidney Kimmel Cancer Center at Jefferson Health
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ selected allogeneic hematopoietic stem cells are a cell therapy product used as a donor stem cell boost for patients experiencing persistent cytopenias (neutropenia, thrombocytopenia, anemia, and lymphopenia) following an initial allogeneic hematopoietic stem cell transplant. Developed and administered at the Sidney Kimmel Cancer Center at Thomas Jefferson University, this therapy utilizes the CliniMACS CD34 Reagent System by Miltenyi Biotec to immunomagnetically select and enrich CD34+ hematopoietic progenitor cells from a donor's peripheral blood apheresis product. This process simultaneously depletes T cells to minimize the risk of graft-versus-host disease (GvHD). The enriched stem cells are intended to enhance hematopoietic reconstitution and restore normal blood cell counts in the recipient.
- Other names
- donor stem cell boostCD34+ selected donor stem cell boostallogeneic hematopoietic stem cell transplantation boostCliniMACS CD34+ selected cells
Beyond the preview
Go deeper on CD34+ selected allogeneic hematopoietic stem cells (Sidney Kimmel Cancer Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ selected allogeneic hematopoietic stem cells (Sidney Kimmel Cancer Center).